The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

被引:0
作者
Jordane Divoux
Romane Florent
Margaux Jacobs
Justine Lequesne
Jean-Michel Grellard
Chankannira San
Sara Grossi
Katia Kerdja
Bénédicte Clarisse
Gwenaelle Boudier
François Cherifi
Mélanie Briand
Enora Dolivet
Alisson Johnson
Brice Dubois
Valentin Harter
Joëlle Lacroix
Charlotte Raboutet
Brigitte Marie
Nathalie Rousseau
Cécile Blanc-Fournier
Dominique Vaur
Martin Figeac
Laurent Poulain
Louis-Bastien Weiswald
George Emile
机构
[1] Université de Caen Normandie,INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers)
[2] UNICANCER,Comprehensive Cancer Center François Baclesse
[3] Université de Caen Normandie,US PLATON, ORGAPRED Core Facility
[4] UNICANCER,Comprehensive Cancer Center François Baclesse, Breast Cancer Unit
[5] Institut Normand du Sein,Comprehensive Cancer Center François Baclesse, Clinical Research Department
[6] UNICANCER,US PLATON, Biological Resource Center ‘OvaRessources’
[7] Université de Caen Normandie,Comprehensive Cancer Center François Baclesse, Department of Surgery
[8] UNICANCER,Comprehensive Cancer Center François Baclesse, North
[9] UNICANCER,West Canceropole Data Center
[10] UNICANCER,Comprehensive Cancer Center François Baclesse, Department of Radiology
[11] IRCBN Institut Régional du Cancer Basse Normandie,Biological Resource Center ‘Tumorotheque de Caen Basse
[12] UNICANCER,Normandie’
[13] UNICANCER,Comprehensive Cancer Center François Baclesse, Department of Biopathology
[14] University of Lille,Comprehensive Cancer Center François Baclesse, Department of Cancer Biology and Genetics
[15] Comprehensive Cancer Center François Baclesse,CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41
[16] Comprehensive Cancer Center François Baclesse, UAR 2014
关键词
Triple negative breast cancer; Patient-derived tumor organoids; Predictive functional assays; Chemo-immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 169 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2020)Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study Lancet Glob Health 8 e1027-e1037
[3]  
Siegel RL(2021)The global breast cancer initiative: a strategic collaboration to strengthen health care for non-communicable diseases Lancet Oncol 22 578-581
[4]  
Laversanne M(2009)Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer Clin Breast Cancer 9 Suppl 2 S73-81
[5]  
Soerjomataram I(2008)Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275-81
[6]  
Jemal A(2022)Event-free survival with pembrolizumab in early triple-negative breast cancer N Engl J Med. 386 556-67
[7]  
Heer E(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med 376 2147-59
[8]  
Harper A(2021)Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer N Engl J Med 384 2394-405
[9]  
Escandor N(2021)VP7–2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC Ann Oncol 32 1198-200
[10]  
Sung H(2021)Tumor organoids: opportunities and challenges to guide precision medicine Cancer Cell 39 1190-1201